↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Collegium Pharmaceutical$COLL · filed: grew revenue 23.6% in FY2025 to $781MNew shipTrillion Score 506Fall Risk MediumNext year $733M–$1.2B sealedCheck ▾Close ▴
What Collegium Pharmaceutical filed
Grew revenue 23.6% in FY2025 to $781 million, operating margin 23.0% against a -3.8% median for pharmaceutical preparations, equity 18.2% of assets. Every figure links to the filing it came from on Collegium Pharmaceutical’s card. New ship: no warning signs. Trillion Score 506, #88 of 182 in its field; Fall Risk Medium (how it is measured).
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $733M and $1.2B, an 80% range sealed on 27 Sept 2026 · receipt #e74cc0 · graded in public by the revenue in Collegium Pharmaceutical’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Collegium commits **3.6%** of market cap to buyback with limited pipeline, signaling confidence or lack of M&A alternatives.
$50 million
accelerated share repurchase program Thursday morning
$40
with a market capitalization just under
$1.4 billion
—now returns roughly
3.6%
of equity value to shareholders in a single transaction
Collegium Pharmaceutical authorized a $50 million accelerated share repurchase program Thursday morning, taking initial delivery from Goldman Sachs and moving premarket shares higher before the bell. The biotech—trading near $40 with a market capitalization just under $1.4 billion—now returns roughly 3.6% of equity value to shareholders in a single transaction, an unusually aggressive move for a company with two marketed products and limited pipeline visibility.
The ASR structure means Collegium receives approximately 80% of the shares immediately, with final settlement contingent on volume-weighted average pricing through an undisclosed future date, typically 60 to 90 days. Goldman Sachs will purchase shares in the open market during that window, and Collegium will either receive additional shares or remit cash depending on the realized average price. The company did not disclose authorization for further buybacks beyond this tranche, nor did it update full-year capital allocation guidance.
Collegium generates substantially all revenue from Jornay PM, a delayed-release methylphenidate for ADHD with differentiated evening dosing, and Belbuca, a buccal buprenorphine film for chronic pain. The ADHD market remains structurally durable—pediatric diagnoses continue rising and adult treatment rates lag prevalence—but Collegium competes in a category where payer pressure intensifies annually and branded exclusivity windows compress. The pain franchise, meanwhile, carries reimbursement and utilization headwinds common to opioid-adjacent therapies. That the board authorized a buyback of this size suggests management believes current valuation meaningfully underprices cash generation from these two assets, or that alternative deployment options—acquisitions, pipeline investment—offer insufficient return.
The timing matters. Collegium reported $109 million in cash and equivalents at the end of Q3 2024, with trailing twelve-month operating cash flow near $80 million. A $50 million buyback at this cash position implies either confidence in near-term cash generation or acceptance of leverage if an acquisition target materializes. Specialty pharma names with concentrated product portfolios typically trade at steep discounts to diversified peers, and Collegium's valuation reflects that: forward enterprise value to sales sits near 2.5x, well below the 4x to 6x range for higher-growth neurology franchises. The buyback is a direct bet that market skepticism overstates franchise risk.
Operators should watch for ASR completion disclosure in the 10-Q filing for Q1 2025, expected late April or early May, which will clarify total shares retired and any cash true-up. Collegium has not guided to additional tranches, but the absence of a broader authorization ceiling suggests this may be a one-time opportunistic move rather than the start of a multi-year capital return program. Payer dynamics for Jornay PM—particularly any utilization management changes from the top-three PBMs—will dictate whether the company can sustain buybacks without constraining operating flexibility.
The premarket bounce reflects a market that prices Collegium as ex-growth. The buyback does not alter that view. It confirms management believes the current price leaves value on the table, and that they would rather own their own equity than deploy the capital elsewhere.
Branded by POPS4 · proof in 60 seconds
For the principal
Buyback at this leverage implies Collegium sees no accretive acquisition targets; track whether they add tranches or go quiet.
For the operator
ASR settlement in 60-90 days will reveal true cost basis; compare to any insider sales in the same window.
For the house
Short-term volatility compression likely; avoid new exposure until Q1 guidance clarifies whether buyback is recurring or one-time capital event.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
